The Novel Imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) Is a Highly Selective Inhibitor of the Inducible Nitric-Oxide Synthase
We have identified imidazopyridine derivatives as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (n...
Gespeichert in:
Veröffentlicht in: | Molecular pharmacology 2006-01, Vol.69 (1), p.328-337 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 337 |
---|---|
container_issue | 1 |
container_start_page | 328 |
container_title | Molecular pharmacology |
container_volume | 69 |
creator | Strub, Andreas Ulrich, Wolf-Rüdiger Hesslinger, Christian Eltze, Manfrid Fuchß, Thomas Strassner, Jochen Strand, Susanne Lehner, Martin D. Boer, Rainer |
description | We have identified imidazopyridine derivatives as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 μM, and 162 μM, respectively. Inhibition of inducible NO synthase was competitive with l-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance experiments, BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 μM, and >500 μM, respectively. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher l-arginine concentrations in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines up to high micromolar concentrations. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC50 = 7 μM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC50 > 100 μM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC50 > 100 μM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new highly selective iNOS inhibitor structurally unrelated to known compounds and l-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo. |
doi_str_mv | 10.1124/mol.105.017087 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1124_mol_105_017087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026895X24050405</els_id><sourcerecordid>16223957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c327t-2c8581368cd17e4d95377245ec1dd8824b6615c0f42d812b3bb36d13fbeeaea93</originalsourceid><addsrcrecordid>eNp1kMFu1DAQhi0EokvhyhH5gtRKePHYceIcS0W7Kwo9tEigqrISe9IYJeuVky4Nr8RL4iorOHHyaOb7rJmfkNfAlwAie9-HbglcLTkUXBdPyAKUAMYB4ClZcC5ypkv17YC8GIYfnEOmNH9ODiAXQpaqWJDf1y3SL2GHHV333lW_wnaK3vkNUsFuBDvK2Gcc2_Awsf2ACTZ1xyw1p-6WyRXzs3eTvVOsvv2rH334_glK4EIe0_VAK7ryd2030Svs0I5-h3S9aX3txxBpaOjYPjbcvfV1lzbyY_SWXT54h_Rq2oxtNeBL8qypugFf7d9D8vXs4_Xpil1cnq9PTy6YlaIYmbBaaZC5tg4KzFypZFGITKEF57QWWZ3noCxvMuE0iFrWtcwdyKZGrLAq5SFZzv_aGIYhYmO20fdVnAxw85i6SamnWpk59SS8mYXtfd2j-4fvY07A2xloUwY_fUSzbavYVzZ04W4yeWnASKETp2cO03k7j9EM1uPGokuOHY0L_n87_AEKKJ0j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Novel Imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) Is a Highly Selective Inhibitor of the Inducible Nitric-Oxide Synthase</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Strub, Andreas ; Ulrich, Wolf-Rüdiger ; Hesslinger, Christian ; Eltze, Manfrid ; Fuchß, Thomas ; Strassner, Jochen ; Strand, Susanne ; Lehner, Martin D. ; Boer, Rainer</creator><creatorcontrib>Strub, Andreas ; Ulrich, Wolf-Rüdiger ; Hesslinger, Christian ; Eltze, Manfrid ; Fuchß, Thomas ; Strassner, Jochen ; Strand, Susanne ; Lehner, Martin D. ; Boer, Rainer</creatorcontrib><description>We have identified imidazopyridine derivatives as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 μM, and 162 μM, respectively. Inhibition of inducible NO synthase was competitive with l-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance experiments, BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 μM, and >500 μM, respectively. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher l-arginine concentrations in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines up to high micromolar concentrations. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC50 = 7 μM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC50 > 100 μM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC50 > 100 μM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new highly selective iNOS inhibitor structurally unrelated to known compounds and l-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo.</description><identifier>ISSN: 0026-895X</identifier><identifier>EISSN: 1521-0111</identifier><identifier>DOI: 10.1124/mol.105.017087</identifier><identifier>PMID: 16223957</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Aorta, Thoracic - drug effects ; Aorta, Thoracic - enzymology ; Arginine - pharmacology ; Cell Line ; Enzyme Inhibitors - chemistry ; Enzyme Inhibitors - pharmacology ; Humans ; Imidazoles - chemistry ; Imidazoles - pharmacology ; In Vitro Techniques ; Male ; Nitric Oxide Synthase Type II - antagonists & inhibitors ; Nitric Oxide Synthase Type III - antagonists & inhibitors ; Pyridines - chemistry ; Pyridines - pharmacology ; Rabbits ; Radioligand Assay ; Rats ; Rats, Wistar ; Structure-Activity Relationship</subject><ispartof>Molecular pharmacology, 2006-01, Vol.69 (1), p.328-337</ispartof><rights>2006 American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c327t-2c8581368cd17e4d95377245ec1dd8824b6615c0f42d812b3bb36d13fbeeaea93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16223957$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strub, Andreas</creatorcontrib><creatorcontrib>Ulrich, Wolf-Rüdiger</creatorcontrib><creatorcontrib>Hesslinger, Christian</creatorcontrib><creatorcontrib>Eltze, Manfrid</creatorcontrib><creatorcontrib>Fuchß, Thomas</creatorcontrib><creatorcontrib>Strassner, Jochen</creatorcontrib><creatorcontrib>Strand, Susanne</creatorcontrib><creatorcontrib>Lehner, Martin D.</creatorcontrib><creatorcontrib>Boer, Rainer</creatorcontrib><title>The Novel Imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) Is a Highly Selective Inhibitor of the Inducible Nitric-Oxide Synthase</title><title>Molecular pharmacology</title><addtitle>Mol Pharmacol</addtitle><description>We have identified imidazopyridine derivatives as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 μM, and 162 μM, respectively. Inhibition of inducible NO synthase was competitive with l-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance experiments, BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 μM, and >500 μM, respectively. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher l-arginine concentrations in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines up to high micromolar concentrations. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC50 = 7 μM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC50 > 100 μM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC50 > 100 μM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new highly selective iNOS inhibitor structurally unrelated to known compounds and l-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo.</description><subject>Animals</subject><subject>Aorta, Thoracic - drug effects</subject><subject>Aorta, Thoracic - enzymology</subject><subject>Arginine - pharmacology</subject><subject>Cell Line</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Imidazoles - chemistry</subject><subject>Imidazoles - pharmacology</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Nitric Oxide Synthase Type II - antagonists & inhibitors</subject><subject>Nitric Oxide Synthase Type III - antagonists & inhibitors</subject><subject>Pyridines - chemistry</subject><subject>Pyridines - pharmacology</subject><subject>Rabbits</subject><subject>Radioligand Assay</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Structure-Activity Relationship</subject><issn>0026-895X</issn><issn>1521-0111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFu1DAQhi0EokvhyhH5gtRKePHYceIcS0W7Kwo9tEigqrISe9IYJeuVky4Nr8RL4iorOHHyaOb7rJmfkNfAlwAie9-HbglcLTkUXBdPyAKUAMYB4ClZcC5ypkv17YC8GIYfnEOmNH9ODiAXQpaqWJDf1y3SL2GHHV333lW_wnaK3vkNUsFuBDvK2Gcc2_Awsf2ACTZ1xyw1p-6WyRXzs3eTvVOsvv2rH334_glK4EIe0_VAK7ryd2030Svs0I5-h3S9aX3txxBpaOjYPjbcvfV1lzbyY_SWXT54h_Rq2oxtNeBL8qypugFf7d9D8vXs4_Xpil1cnq9PTy6YlaIYmbBaaZC5tg4KzFypZFGITKEF57QWWZ3noCxvMuE0iFrWtcwdyKZGrLAq5SFZzv_aGIYhYmO20fdVnAxw85i6SamnWpk59SS8mYXtfd2j-4fvY07A2xloUwY_fUSzbavYVzZ04W4yeWnASKETp2cO03k7j9EM1uPGokuOHY0L_n87_AEKKJ0j</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>Strub, Andreas</creator><creator>Ulrich, Wolf-Rüdiger</creator><creator>Hesslinger, Christian</creator><creator>Eltze, Manfrid</creator><creator>Fuchß, Thomas</creator><creator>Strassner, Jochen</creator><creator>Strand, Susanne</creator><creator>Lehner, Martin D.</creator><creator>Boer, Rainer</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200601</creationdate><title>The Novel Imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) Is a Highly Selective Inhibitor of the Inducible Nitric-Oxide Synthase</title><author>Strub, Andreas ; Ulrich, Wolf-Rüdiger ; Hesslinger, Christian ; Eltze, Manfrid ; Fuchß, Thomas ; Strassner, Jochen ; Strand, Susanne ; Lehner, Martin D. ; Boer, Rainer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c327t-2c8581368cd17e4d95377245ec1dd8824b6615c0f42d812b3bb36d13fbeeaea93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Aorta, Thoracic - drug effects</topic><topic>Aorta, Thoracic - enzymology</topic><topic>Arginine - pharmacology</topic><topic>Cell Line</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Imidazoles - chemistry</topic><topic>Imidazoles - pharmacology</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Nitric Oxide Synthase Type II - antagonists & inhibitors</topic><topic>Nitric Oxide Synthase Type III - antagonists & inhibitors</topic><topic>Pyridines - chemistry</topic><topic>Pyridines - pharmacology</topic><topic>Rabbits</topic><topic>Radioligand Assay</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strub, Andreas</creatorcontrib><creatorcontrib>Ulrich, Wolf-Rüdiger</creatorcontrib><creatorcontrib>Hesslinger, Christian</creatorcontrib><creatorcontrib>Eltze, Manfrid</creatorcontrib><creatorcontrib>Fuchß, Thomas</creatorcontrib><creatorcontrib>Strassner, Jochen</creatorcontrib><creatorcontrib>Strand, Susanne</creatorcontrib><creatorcontrib>Lehner, Martin D.</creatorcontrib><creatorcontrib>Boer, Rainer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Molecular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strub, Andreas</au><au>Ulrich, Wolf-Rüdiger</au><au>Hesslinger, Christian</au><au>Eltze, Manfrid</au><au>Fuchß, Thomas</au><au>Strassner, Jochen</au><au>Strand, Susanne</au><au>Lehner, Martin D.</au><au>Boer, Rainer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Novel Imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) Is a Highly Selective Inhibitor of the Inducible Nitric-Oxide Synthase</atitle><jtitle>Molecular pharmacology</jtitle><addtitle>Mol Pharmacol</addtitle><date>2006-01</date><risdate>2006</risdate><volume>69</volume><issue>1</issue><spage>328</spage><epage>337</epage><pages>328-337</pages><issn>0026-895X</issn><eissn>1521-0111</eissn><abstract>We have identified imidazopyridine derivatives as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 μM, and 162 μM, respectively. Inhibition of inducible NO synthase was competitive with l-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance experiments, BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 μM, and >500 μM, respectively. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher l-arginine concentrations in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines up to high micromolar concentrations. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC50 = 7 μM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC50 > 100 μM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC50 > 100 μM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new highly selective iNOS inhibitor structurally unrelated to known compounds and l-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16223957</pmid><doi>10.1124/mol.105.017087</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0026-895X |
ispartof | Molecular pharmacology, 2006-01, Vol.69 (1), p.328-337 |
issn | 0026-895X 1521-0111 |
language | eng |
recordid | cdi_crossref_primary_10_1124_mol_105_017087 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
subjects | Animals Aorta, Thoracic - drug effects Aorta, Thoracic - enzymology Arginine - pharmacology Cell Line Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Humans Imidazoles - chemistry Imidazoles - pharmacology In Vitro Techniques Male Nitric Oxide Synthase Type II - antagonists & inhibitors Nitric Oxide Synthase Type III - antagonists & inhibitors Pyridines - chemistry Pyridines - pharmacology Rabbits Radioligand Assay Rats Rats, Wistar Structure-Activity Relationship |
title | The Novel Imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) Is a Highly Selective Inhibitor of the Inducible Nitric-Oxide Synthase |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A08%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Novel%20Imidazopyridine%202-%5B2-(4-Methoxy-pyridin-2-yl)-ethyl%5D-3H-imidazo%5B4,5-b%5Dpyridine%20(BYK191023)%20Is%20a%20Highly%20Selective%20Inhibitor%20of%20the%20Inducible%20Nitric-Oxide%20Synthase&rft.jtitle=Molecular%20pharmacology&rft.au=Strub,%20Andreas&rft.date=2006-01&rft.volume=69&rft.issue=1&rft.spage=328&rft.epage=337&rft.pages=328-337&rft.issn=0026-895X&rft.eissn=1521-0111&rft_id=info:doi/10.1124/mol.105.017087&rft_dat=%3Cpubmed_cross%3E16223957%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16223957&rft_els_id=S0026895X24050405&rfr_iscdi=true |